Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

951 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of first onset of colorectal cancer associated with alcohol consumption in Lynch syndrome: a multicenter cohort study.
Fujiyoshi K, Sudo T, Fujita F, Chino A, Akagi K, Takao A, Yamada M, Tanakaya K, Ishida H, Komori K, Ishihara S, Miguchi M, Hirata K, Miyakura Y, Ishikawa T, Yamaguchi T, Tomita N, Ajioka Y, Sugihara K. Fujiyoshi K, et al. Among authors: komori k. Int J Clin Oncol. 2022 Jun;27(6):1051-1059. doi: 10.1007/s10147-022-02148-2. Epub 2022 Mar 23. Int J Clin Oncol. 2022. PMID: 35320449
Clinical significance of the mesorectal extension of rectal cancer: a Japanese multi-institutional study.
Shirouzu K, Akagi Y, Fujita S, Ueno H, Takii Y, Komori K, Ito M, Sugihara K; Japanese Society for Cancer of the Colon and Rectum (JSCCR) on Clinical Significance of the Mesorectal Extension of Rectal Cancer. Shirouzu K, et al. Among authors: komori k. Ann Surg. 2011 Apr;253(4):704-10. doi: 10.1097/SLA.0b013e3182119331. Ann Surg. 2011. PMID: 21475010
Predicting oncologic outcomes by stratifying mesorectal extension in patients with pT3 rectal cancer: a Japanese multi-institutional study.
Akagi Y, Shirouzu K, Fujita S, Ueno H, Takii Y, Komori K, Ito M, Sugihara K; Study Group of the Japanese Society for Cancer of the Colon and Rectum (JSCCR) on the Clinical Significance of the Mesorectal Extension of Rectal Cancer. Akagi Y, et al. Among authors: komori k. Int J Cancer. 2012 Sep 1;131(5):1220-7. doi: 10.1002/ijc.27315. Epub 2012 Jan 3. Int J Cancer. 2012. PMID: 22025276
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Shitara K, Matsuo K, Kondo C, Takahari D, Ura T, Inaba Y, Yamaura H, Sato Y, Kato M, Kanemitsu Y, Komori K, Ishiguro S, Sano T, Shimizu Y, Muro K. Shitara K, et al. Among authors: komori k. Oncology. 2011;81(3-4):167-74. doi: 10.1159/000333404. Epub 2011 Nov 1. Oncology. 2011. PMID: 22057124
Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review.
Ueno H, Hase K, Hashiguchi Y, Shimazaki H, Yoshii S, Kudo SE, Tanaka M, Akagi Y, Suto T, Nagata S, Matsuda K, Komori K, Yoshimatsu K, Tomita Y, Yokoyama S, Shinto E, Nakamura T, Sugihara K. Ueno H, et al. Among authors: komori k. J Gastroenterol. 2014 Sep;49(9):1314-23. doi: 10.1007/s00535-013-0881-3. Epub 2013 Sep 25. J Gastroenterol. 2014. PMID: 24065123
A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
Taniguchi H, Komori A, Narita Y, Kadowaki S, Ura T, Andoh M, Yatabe Y, Komori K, Kimura K, Kinoshita T, Muro K. Taniguchi H, et al. Among authors: komori k, komori a. Jpn J Clin Oncol. 2016 Mar;46(3):228-33. doi: 10.1093/jjco/hyv193. Epub 2016 Jan 12. Jpn J Clin Oncol. 2016. PMID: 26759349
951 results